Sanofi Reports Positive Results from Diabetes Drug Study

The study evaluated the efficacy and safety of lixisenatide as an add-on therapy for people with type 2 diabetes whose condition was inadequately controlled by sulfonylureas.

Sanofi-Aventis has reported positive results from the Phase III study evaluating lixisenatide, a once-daily GLP-1 receptor agonist under development for people with type 2 diabetes. The study achieved its primary efficacy objective of significant HbA1c reduction and improved glycemic control from baseline versus placebo.

The top-line results also revealed that people treated with lixisenatide had a significant decrease in body weight.

The randomised, double-blind, placebo-controlled study was one of nine in the Phase III clinical programme with a 24-week main treatment period.

The study evaluated the effi